OGFR Antagonist Local Delivery for Selective Tumor Cytotoxicity

Solution Overview

Problem

Current cancer treatment strategies lack a uniform and effective approach, as most cancers remain incurable despite advances in understanding cancer mechanisms.

Innovation Solution

The method involves locally administering an opioid growth factor receptor (OGFR) antagonist, such as naloxone, naltrexone, or their derivatives, directly to the site of cancer cells using a carrier like a collagen sponge or hydrogel.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional cancer treatment strategies (surgery, chemotherapy, radiation therapy) are used, then some cancers can be treated, but most cancers remain incurable and there is no uniform effective treatment approach

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies universality by using a single treatment approach (OGFR antagonist administration) that can be applied across multiple cancer types. The invention targets a common mechanism (OGFR signaling) that is aberrant in various cancers including breast cancer, lung cancer, and other carcinomas, providing a universal treatment strategy rather than cancer-type-specific approaches

Inventive Principle:
Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent employs parameter changes by administering the OGFR antagonist at high local concentrations (1-10 mM) directly to the tumor site, which is significantly higher than systemic concentrations. This parameter change in local concentration enables effective tumor cell killing while sparing normal cells that are not exposed to such high concentrations

Inventive Principle:
Principle #35Parameter changes

2Reliability

If high concentration of OGFR antagonist is administered locally to tumor cells, then selective cytotoxicity in tumor cells is achieved, but the complexity of local administration increases

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses a carrier or vehicle as an intermediary to deliver the OGFR antagonist to the tumor site. This carrier facilitates local administration by transporting the high concentration of antagonist directly to the tumor cells while minimizing exposure to surrounding normal tissues, thus simplifying the overall administration process

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent applies local quality by creating a high concentration gradient of the OGFR antagonist that is localized specifically at the tumor site. The treatment exhibits different concentrations at different locations: very high concentration at the tumor site versus negligible concentration in surrounding normal tissues, achieving selective cytotoxicity through spatial differentiation

Inventive Principle:
Principle #3Local quality

Data Source

PatentUS12310962B2Methods and compositions for treating cancer
Publication Date: 2025.05.27
  • US12310962B2 patent drawing
  • US12310962B2 patent drawing
  • US12310962B2 patent drawing

AI summary

This disclosure relates to methods and compositions for treating cancer by administering opioid growth factor receptor (OGFR) antagonists. In particular, the present disclosure relates to methods of administering OGFR antagonists locally to the site of cancer cells in the patient diagnosed with cancer.